Working… Menu
Trial record 64 of 144 for:    "Acute promyelocytic leukemia"

Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01361334
Recruitment Status : Completed
First Posted : May 26, 2011
Last Update Posted : March 15, 2017
Information provided by (Responsible Party):
University Hospital Muenster

Brief Summary:
Long term disease-free survival (DFS) of patients with acute myeloid leukemia (AML) is still poor. Recently, so-called "targeted therapy" for cancer has been introduced to the treatment of patients with AML. This phase II clinical trial will explore the efficacy, safety, and pharmacodynamics of the tyrosine kinase inhibitor pazopanib in patients with relapsed or refractory AML or patients with AML who are not eligible for intensive treatment. Biomarker studies will be included to study whether the targets are indeed inhibited and whether this leads to decreased BM angiogenesis. Toxicity assessments will be included, and the antileukemic effectiveness will be studied.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Pazopanib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
Study Start Date : June 2011
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Arm Intervention/treatment
Experimental: Pazopanib
Pazopanib treatment
Drug: Pazopanib
800 mg QD p.o.
Other Name: Votrient(R)

Primary Outcome Measures :
  1. Cumulative response rate (CR, CRp, CRi, PR) within up to one year of pazopanib treatment [ Time Frame: 12 months ]
  2. Reduction of BM microvessel density on day 28 [ Time Frame: 28 days ]

Secondary Outcome Measures :
  1. Safety and Tolerability (Rate of adverse events) [ Time Frame: 12 months ]
    Rate of adverse events

  2. Cumulative incidence and degree of inhibition of target receptor phosphorylation (PDGFR, VEGFR, and c-KIT) and correlation with clinical response [ Time Frame: 12 months ]
  3. Reduction of BM microvessel density on day 14 [ Time Frame: 14 days ]
  4. Relapse-free survival in relationship to historical control patients, Overall survival in relationship to historical control patients, Duration of response [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects must provide written informed consent prior to performance of study-specific procedures or assessments which are not routinely performed for diagnosis or monitoring of acute myeloid leukemia (AML), and the subjects must be willing to comply with treatment and to follow up assessments and procedures
  2. Histologically or cytologically confirmed diagnosis of AML relapsed after or refractory to at least one induction regimen, or patients with AML at initial diagnosis who are not eligible for allogeneic transplant or intensive induction chemotherapy, except for AML M3 (acute promyelocytic leukemia)
  3. Age at least 18 years
  4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤3
  5. Measurable disease burden (blasts in BM and/or PB, extramedullary blasts [chloroma])
  6. Able to swallow and retain oral medication
  7. A life expectancy of at least 4 weeks
  8. Adequate contraception methods
  9. Adequate organ function as defined in the study protocol

Exclusion Criteria:

  1. Patients with a valid option for intensive chemotherapy and/or stem cell transplantation (Patients after allogeneic stem cell transplant must be off immunosuppressive agents for at least 2 weeks prior to study entry and Graft-versus host disease must have resolved to Grade ≤2)
  2. History of cancer that according to the Investigator might confound the assessment of the endpoints of the study
  3. Uncontrolled peptic ulcer disease or clinically significant gastrointestinal abnormalities which interfere with oral dosing or any unstable or serious concurrent condition (e.g., active uncontrolled infection)
  4. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥90 mmHg]. Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. BP must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values from each BP assessment must be <140/90 mmHg in order for a subject to be eligible for the study
  5. Prolongation of corrected QT interval (QTc) >480 milliseconds
  6. History of any one of more of the following cardiovascular conditions within the past 6 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina, symptomatic peripheral vascular disease, class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)
  7. History of cerebrovascular infarction or bleeding, pulmonary embolism, or untreated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulant agents for at least 6 weeks are eligible
  8. Evidence of serious active bleeding or bleeding diathesis (except for bleeding or petechiae due to AML-related thrombocytopenia which will be treated using platelet transfusions). Also, patients with known endobronchial lesions and/or lesions infiltrating major pulmonary vessels will be excluded from the study due to excess risk of bleeding.
  9. Prior major surgery or trauma within 28 days prior to first dose of study drug
  10. Treatment with an investigational agent within 28 days or 5 half-lives, whichever is longer prior to the first dose of study drug (for bevacizumab 60 days).
  11. Concurrent cytoreductive chemotherapy (hydroxyurea must be discontinued at least one day before start of study medication)
  12. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to pazopanib
  13. Patients with psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
  14. Pregnant or lactating and actively breastfeeding patients
  15. Patients taking any of the following prohibited medication:

    • clarithromycin, telithromycin, troleandomycin (antibiotics)
    • ritonavir, indinavir, saquinavir, nelfinavir, amprenavir, lopinavir (HIV protease inhibitors)
    • itraconazole, ketoconazole, voriconazole, fluconazole (antifungals)
    • nefazodone (antidepressant)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01361334

Layout table for location information
Unviersity Hospital of Münster (UKM)
Münster, Germany, 48149
Sponsors and Collaborators
University Hospital Muenster
Layout table for investigator information
Principal Investigator: Torsten Kessler, MD University of Münster, Department of Medicine A, Germany

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University Hospital Muenster Identifier: NCT01361334     History of Changes
Other Study ID Numbers: UKM09_0018_PAZOPANIB_AML 2011
2010-024526-37 ( EudraCT Number )
First Posted: May 26, 2011    Key Record Dates
Last Update Posted: March 15, 2017
Last Verified: May 2016
Keywords provided by University Hospital Muenster:
(other than AML M3)
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type